BMY.N
現在値
59.49USD変化
1.24(+2.13%)出来高
2,557,925本日のレンジ
-
59.8352週レンジ
-
68.34∙ 約20分前の相場を表示しています。
Sept 24 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::OPDIVO (NIVOLUMAB) SIGNIFICANTLY IMPROVES DISEASE FREE-SURVIVAL VERSUS. PLACEBO AS ADJUVANT THERAPY FOR PATIENTS WITH HIGH-RISK, MUSCLE-INVASIVE UROTHELIAL CARCINOMA IN PHASE 3 CHECKMATE -274 TRIAL.BRISTOL-MYERS SQUIBB CO - IN AN INTERIM ANALYSIS, CHECKMATE -274 MET PRIMARY ENDPOINTS OF DISEASE-FREE SURVIVAL.BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN SOLID TUMORS.BRISTOL-MYERS SQUIBB CO - PLANS TO COMPLETE A FULL EVALUATION OF CHECKMATE -274 DATA.
Sept 22 (Reuters) - bluebird bio Inc <BLUE.O>::U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS FOR PRIORITY REVIEW BRISTOL MYERS SQUIBB AND BLUEBIRD BIO APPLICATION FOR ANTI-BCMA CAR T CELL THERAPY IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121).BRISTOL-MYERS SQUIBB CO - FDA SET A TARGET ACTION DATE OF MARCH 27, 2021.BRISTOL-MYERS SQUIBB CO - BLA IS BASED ON RESULTS FROM PIVOTAL PHASE 2 KARMMA STUDY.
Sept 21 (Reuters) - BRISTOL MYERS ::BRISTOL MYERS - ANNOUNCED PRIMARY RESULTS FROM PHASE 3 CHECKMATE -649 TRIAL IN FIRST-LINE SETTING FOR PATIENTS WITH GASTRIC AND ESOPHAGEAL CANCERS.BRISTOL MYERS - IN PHASE 3 CHECKMATE -649 TRIAL, OPDIVO PLUS CHEMOTHERAPY SHOWED SIGNIFICANT PROGRESSION-FREE SURVIVAL BENEFITS VERSUS CHEMOTHERAPY.BRISTOL MYERS - IN PHASE 3 CHECKMATE -649 TRIAL, OPDIVO PLUS CHEMOTHERAPY SHOWED SIGNIFICANT OVERALL SURVIVAL BENEFITS VERSUS CHEMOTHERAPY.BRISTOL MYERS - EFFICACY BENEFIT OBSERVED ACROSS PATIENTS WITH GASTRIC CANCER, GASTROESOPHAGEAL JUNCTION CANCER OR ESOPHAGEAL ADENOCARCINOMA IN PHASE 3 TRIAL.BRISTOL MYERS - INCIDENCE OF TREATMENT-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH OPDIVO PLUS CHEMOTHERAPY WAS CONSISTENT ACROSS SUB-GROUPS.BRISTOL MYERS - INCIDENCE OF SERIOUS TRAES, ANY GRADE AND GRADE 3-4, WAS MODESTLY HIGHER AMONG PATIENTS TREATED WITH OPDIVO PLUS CHEMOTHERAPY.
Sept 19 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::OPDIVO® (NIVOLUMAB) IN COMBINATION WITH CABOMETYX® (CABOZANTINIB) DEMONSTRATES SIGNIFICANT SURVIVAL BENEFITS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN PIVOTAL PHASE 3 CHECKMATE -9ER TRIAL.BRISTOL-MYERS SQUIBB-DEMONSTRATED SIGNIFICANT IMPROVEMENTS ACROSS ALL EFFICACY ENDPOINTS, INCLUDING OS, IN PREVIOUSLY UNTREATED ADVANCED RCC.BRISTOL-MYERS SQUIBB-CO AND EXELIXIS’ PARTNER IPSEN, SUBMITTED TYPE II VARIATION APPLICATIONS FOR OPDIVO PLUS CABOMETYX TO THE EMA.
Sept 17 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES SETTLEMENT OF U.S. REVLIMID (LENALIDOMIDE) CAPSULES PATENT LITIGATION WITH CELGENE.CELGENE TO PROVIDE CO WITH LICENSE TO SELL VOLUME-LIMITED AMOUNTS OF GENERIC LENALIDOMIDE CAPSULES IN U.S..AGREED-UPON SALES VOLUME PERCENTAGES CONFIDENTIAL.ALSO LICENSED TO SELL GENERIC LENALIDOMIDE IN U.S. WITHOUT VOLUME LIMIT.LICENSE TO SELL VOLUME-LIMITED AMOUNTS OF GENERIC LENALIDOMIDE CAPSULES IN U.S. BEGINS ON CONFIDENTIAL DATE AFTER MARCH 2022.
Bristol-Myers Squibb Co <BMY.N>::BRISTOL-MYERS SQUIBB CO - DECLARED A QUARTERLY DIVIDEND OF $0.45 PER SHARE.
Sept 1 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES ONUREG® (AZACITIDINE TABLETS), A NEW ORAL THERAPY, AS CONTINUED TREATMENT FOR ADULTS IN FIRST REMISSION WITH ACUTE MYELOID LEUKEMIA.BRISTOL-MYERS - IN STUDY, ONUREG SIGNIFICANTLY IMPROVED OVERALL SURVIVAL BY NEARLY 10 MONTHS VERSUS PLACEBO.
Sept 1 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB ANNOUNCES INTERIM RESULTS FROM LONG-TERM STUDY REINFORCING EFFICACY AND SAFETY PROFILE OF ZEPOSIA (OZANIMOD) IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.BRISTOL MYERS SQUIBB ANNOUNCES INTERIM RESULTS FROM LONG-TERM STUDY REINFORCING EFFICACY AND SAFETY PROFILE OF ZEPOSIA (OZANIMOD) IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.BRISTOL-MYERS - DAYBREAK TRIAL REPRESENTS LONGEST SAFETY, EFFICACY ANALYSIS OF ZEPOSIA IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS TO DATE.BRISTOL-MYERS SQUIBB CO - MAJORITY OF PATIENTS WERE RELAPSE-FREE AT MONTHS 24 AND 36 IN EXTENSION STUDY AND NO NEW SAFETY CONCERNS EMERGED.BRISTOL-MYERS SQUIBB - IN DAYBREAK TRIAL, 81.8% PARTICIPANTS HAD ANY TREATMENT-EMERGENT ADVERSE EVENT, 9.5% HAD SERIOUS TEAE, 2.2% DISCONTINUED STUDY DUE TO A TEAE.BRISTOL-MYERS SQUIBB - MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS WERE NASOPHARYNGITIS, HEADACHE, UPPER RESPIRATORY TRACT INFECTION & LYMPHOPENIA.
Aug 25 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB PROVIDES UPDATE ON PHASE 3 IDHENTIFY TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.BRISTOL-MYERS - WILL COMPLETE A FULL EVALUATION OF IDHENTIFY DATA AND WORK WITH INVESTIGATORS TO PRESENT DETAILED RESULTS AT A FUTURE MEDICAL MEETING.BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF IDHIFA WAS CONSISTENT WITH PREVIOUSLY REPORTED FINDINGS.BRISTOL-MYERS - PHASE 3 IDHENTIFY STUDY DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.
Aug 24 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB ENTERS AGREEMENT TO ACQUIRE FORBIUS, ADDING LEAD TGF-BETA ASSET TO PORTFOLIO.BRISTOL-MYERS SQUIBB CO - TRANSACTION INCLUDES AN UPFRONT PAYMENT AND FUTURE SUCCESS-BASED MILESTONE PAYMENTS.BRISTOL-MYERS SQUIBB CO - WOULD ACQUIRE FORBIUS'S TGF-BETA PROGRAM, INCLUDING PROGRAM'S LEAD INVESTIGATIONAL ASSET, AVID200.BRISTOL-MYERS SQUIBB CO - PRIOR TO CLOSING, FORBIUS' NON-TGF-BETA ASSETS WILL BE TRANSFERRED TO A NEWLY FORMED PRIVATE COMPANY.BRISTOL-MYERS SQUIBB CO - INTENDS TO INITIALLY FOCUS RESEARCH AND DEVELOPMENT EFFORTS OF AVID200 IN ONCOLOGY.BRISTOL-MYERS - FORBIUS' NON-TGF-BETA ASSETS WILL BE TRANSFERRED TO A NEWLY FORMED PRIVATE CO, WHICH WILL BE RETAINED BY FORBIUS' EXISTING HOLDERS.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。